Matt Hewitt
Stock Analyst at Craig-Hallum
(2.56)
# 2,231
Out of 4,931 analysts
40
Total ratings
51.35%
Success rate
1.75%
Average return
Main Sectors:
Stocks Rated by Matt Hewitt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLP Simulations Plus | Maintains: Buy | $45 → $36 | $14.06 | +156.05% | 8 | Jun 13, 2025 | |
| CSBR Champions Oncology | Maintains: Buy | $8 → $12 | $6.11 | +96.40% | 4 | Mar 12, 2025 | |
| CLOV Clover Health Investments | Initiates: Buy | $6 | $2.21 | +171.49% | 1 | Dec 17, 2024 | |
| BLFS BioLife Solutions | Maintains: Buy | $30 → $32 | $20.64 | +55.04% | 4 | Nov 13, 2024 | |
| OMCL Omnicell | Maintains: Buy | $45 → $64 | $31.03 | +106.25% | 6 | Oct 31, 2024 | |
| NOTV Inotiv | Maintains: Buy | $25 → $10 | $1.96 | +410.20% | 3 | May 16, 2024 | |
| SDGR Schrödinger | Maintains: Buy | $35 → $30 | $19.36 | +54.96% | 3 | May 2, 2024 | |
| MXCT MaxCyte | Initiates: Buy | $7 | $1.43 | +389.51% | 1 | Nov 29, 2023 | |
| RGEN Repligen | Maintains: Buy | $207 → $200 | $113.52 | +76.18% | 3 | Aug 3, 2023 | |
| OABI OmniAb | Initiates: Buy | $10 | $1.88 | +433.33% | 1 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $67 → $30 | $6.95 | +331.65% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $1.80 | +22,122.22% | 1 | Jan 4, 2022 |
Simulations Plus
Jun 13, 2025
Maintains: Buy
Price Target: $45 → $36
Current: $14.06
Upside: +156.05%
Champions Oncology
Mar 12, 2025
Maintains: Buy
Price Target: $8 → $12
Current: $6.11
Upside: +96.40%
Clover Health Investments
Dec 17, 2024
Initiates: Buy
Price Target: $6
Current: $2.21
Upside: +171.49%
BioLife Solutions
Nov 13, 2024
Maintains: Buy
Price Target: $30 → $32
Current: $20.64
Upside: +55.04%
Omnicell
Oct 31, 2024
Maintains: Buy
Price Target: $45 → $64
Current: $31.03
Upside: +106.25%
Inotiv
May 16, 2024
Maintains: Buy
Price Target: $25 → $10
Current: $1.96
Upside: +410.20%
Schrödinger
May 2, 2024
Maintains: Buy
Price Target: $35 → $30
Current: $19.36
Upside: +54.96%
MaxCyte
Nov 29, 2023
Initiates: Buy
Price Target: $7
Current: $1.43
Upside: +389.51%
Repligen
Aug 3, 2023
Maintains: Buy
Price Target: $207 → $200
Current: $113.52
Upside: +76.18%
OmniAb
Apr 13, 2023
Initiates: Buy
Price Target: $10
Current: $1.88
Upside: +433.33%
Apr 28, 2022
Maintains: Hold
Price Target: $67 → $30
Current: $6.95
Upside: +331.65%
Jan 4, 2022
Initiates: Buy
Price Target: $400
Current: $1.80
Upside: +22,122.22%